Europe watchdog advises suspending 'risky' osteoporosis drug

A committee of Europe's medicines watchdog on Friday recommended suspending the use of an osteoporosis drug, saying the risks, including heart attacks, outweighed the benefits.

The drug, Protelos/Osseor, is prescribed for people with the bone-crumbling disease who often suffer debilitating fractures.

A product of French firm Servier Laboratories, the medicine is said to make bones stronger and prevent breaks.

But the PRAC risk assessment committee of the European Medicines Agency (EMA) said the risks of serious , including heart attacks, blood clots and blocked arteries, were just too great.

For every 1,000 treated patients, there were four additional cases of serious heart problems and four of clotting among people using Protelos/Osseor compared to those given a placebo or dummy treatment.

Other risks include seizures and liver inflammation.

As an osteoporosis treatment, the drug has shown a "modest effect"—preventing about five non-spinal bone fractures, 15 and 0.4 hip fractures per 1,000 patients, the committee said.

"The PRAC weighed the benefits of the medicine against the known risks and concluded that the balance was no longer favourable, and recommended Protelos/Osseor be suspended until there are new data showing a favourable balance in a defined patient group," a statement said.

The recommendation will next be considered by the EMA's Committee for Medicinal Products for Human Use for a final decision.

Servier in a statement informed national health agencies of Friday's announcement, and said it would provide further information once the EMA review is concluded.

add to favorites email to friend print save as pdf

Related Stories

Alendronate reduces adjacent-level vertebral fractures

Dec 30, 2013

(HealthDay)—For females with osteoporosis, the rate of adjacent-level vertebral fractures is relatively low, with reduced odds with bisphosphonate therapy, according to a study published in the Dec. 1 issue ...

Recommended for you

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.